Mass General Brigham Spins Out Generative AI Startup

Mass General Brigham spun out a new company offering a generative AI platform that can rapidly interpret both structured and unstructured clinical data. Right now, the tool’s primary application is to accelerate and improve the accuracy of patient screening for clinical trials. The post Mass General Brigham Spins Out Generative AI Startup appeared first on…

Read More

Hyro Snags $45M for Its Conversational AI Agents

Agentic AI company Hyro has now raised a total of $95 million. Its agents, which automate call center workflows, are used by health systems including Intermountain Healthcare, Bon Secours Mercy Health, Hackensack Meridian Health, Baptist Health and Sutter Health. The post Hyro Snags $45M for Its Conversational AI Agents appeared first on MedCity News.

Read More

Why the DOJ’s Lawsuit Against the UGH-Amedisys Merger May Not Go Anywhere

Experts aren’t sure what the outcome of the DOJ’s recent lawsuit against the proposed UnitedHealth Group/Amedisys merger will be under the incoming Trump administration. The Biden administration has focused more on supporting clinicians, while the previous Trump administration favored corporations. Additionally, one expert noted that this case differs from other antitrust lawsuits because it does…

Read More

Understanding healthcare claim denials: reasons & solutions

Experian Health’s State of Claims 2024 report reveals a worrying trend in healthcare claim denials, with nearly three-quarters of survey respondents reporting a rise. Around four in ten say claims are denied 10% of the time, with one in ten seeing denial rates above 15%. Denials at this scale, driven by various claim denial reasons,…

Read More

Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines

Gilead Sciences exercised its option license a Kymera Therapeutics’ protein-degrading drug designed to eliminate the cancer-driving protein CDK2. Meanwhile, Roche’s new partnership with C4 Therapeutics is focused on developing degrader antibody drug conjugates for undisclosed cancer targets. The post Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines appeared first on MedCity…

Read More